Gauri Lankesh murder: SIT picks up another accused from Kodagu; total climbs to 10

Belthangady, Jul 26: The forest department officials on Sunday banned traffic in Charmadi ghat section as a precautionary measure following information that landslide and uprooting of trees may take place due to heavy rain which has been lashing the ghat section since last one week.

The officials said that a tree was likely to be uprooted in the 6th and 7th cross of the ghat section therefore the entry of vehicles were banned and this has resulted in a traffic jam.

It is said that despite lockdown many vehicles have been playing in the Ghat section.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Wayanad, Jul 6: DM Education and Research Foundation (DMERF), headed by Dr Azad Moopen, has come forward to handover DM WIMS Medical College, Nursing and Pharmacy Colleges and its associated institutions in Wayanad to the Kerala Government. 

According to Azad Moopen, Managing Trustee, DMERF, the Kerala Government has been deliberating to set up a medical college in the area over the last 7-8 years to address the challenges being faced by the local population due to lack of local availability of advanced healthcare facilities under the government sector. 

The handover by DMERF would address the Government's need. DM WIMS is one of the few NABH accredited medical colleges in the country, he said.

The DM WIMS Medical College and its associated institutions were established by the DMERF Trust 10 years ago to help the backward community of the district. 

Run in a charitable manner, the medical college has a capacity of 150 seats and has seen two batches of doctors graduate from the institution. With a total built up area of 14 lakh sq feet, it also has a 700-bed super-specialty hospital catering to the local community and helping in training healthcare professionals, a 100-bed specialty hospital, a pharmacy college, and a nursing college.

A new medical college by the government will require substantial investments and minimum of 5 years to become functional. “We think that DM WIMS can cater to the requirement of the government and setting up another medical college might not be required to cater to the existing population,” he said.

Moopen also announced a donation of Rs 250 crore out of the total investment in the institutions to the government to provide treatment to the needy population in the backward, landlocked district and to train good quality doctors from the State.